ASSESSING CARDIOPROTECTIVE EFFECT OF ERYTHROPIOTEIN IN UREMIC CARDIOMYOPATHY THROUGH MODULATION OF NUCLEAR FACTOR KAPPA -β AND ASSOCIATD PROINFLAMMATORY CYTOKINES
mohamed, D., Elwakeel, H., Said, M., Hussien, N., Elhammady, M. (2022). ASSESSING CARDIOPROTECTIVE EFFECT OF ERYTHROPIOTEIN IN UREMIC CARDIOMYOPATHY THROUGH MODULATION OF NUCLEAR FACTOR KAPPA -β AND ASSOCIATD PROINFLAMMATORY CYTOKINES. EKB Journal Management System, 39(Special issue (Academic)), 141-152. doi: 10.21608/bmfj.2021.36304.1291
dania abdelhady mohamed; Hend Elsayed Elwakeel; Mona AbdelAzim Said; Noha Ibrahim Hussien; Mohammed Samy Elhammady. "ASSESSING CARDIOPROTECTIVE EFFECT OF ERYTHROPIOTEIN IN UREMIC CARDIOMYOPATHY THROUGH MODULATION OF NUCLEAR FACTOR KAPPA -β AND ASSOCIATD PROINFLAMMATORY CYTOKINES". EKB Journal Management System, 39, Special issue (Academic), 2022, 141-152. doi: 10.21608/bmfj.2021.36304.1291
mohamed, D., Elwakeel, H., Said, M., Hussien, N., Elhammady, M. (2022). 'ASSESSING CARDIOPROTECTIVE EFFECT OF ERYTHROPIOTEIN IN UREMIC CARDIOMYOPATHY THROUGH MODULATION OF NUCLEAR FACTOR KAPPA -β AND ASSOCIATD PROINFLAMMATORY CYTOKINES', EKB Journal Management System, 39(Special issue (Academic)), pp. 141-152. doi: 10.21608/bmfj.2021.36304.1291
mohamed, D., Elwakeel, H., Said, M., Hussien, N., Elhammady, M. ASSESSING CARDIOPROTECTIVE EFFECT OF ERYTHROPIOTEIN IN UREMIC CARDIOMYOPATHY THROUGH MODULATION OF NUCLEAR FACTOR KAPPA -β AND ASSOCIATD PROINFLAMMATORY CYTOKINES. EKB Journal Management System, 2022; 39(Special issue (Academic)): 141-152. doi: 10.21608/bmfj.2021.36304.1291

ASSESSING CARDIOPROTECTIVE EFFECT OF ERYTHROPIOTEIN IN UREMIC CARDIOMYOPATHY THROUGH MODULATION OF NUCLEAR FACTOR KAPPA -β AND ASSOCIATD PROINFLAMMATORY CYTOKINES

Benha Medical Journal
Article 221, Volume 39, Special issue (Academic), September and October 2022, Pages 141-152    PDF (1.19 M)
Document Type: Original Article
DOI: 10.21608/bmfj.2021.36304.1291
Authors
dania abdelhady mohamed* 1; Hend Elsayed Elwakeel2; Mona AbdelAzim Said2; Noha Ibrahim Hussien3; Mohammed Samy Elhammady2
1physiology department -banha faculty of medecine- banha university
2Physiology Department, Faculty of Medicine, Benha University.
3Department of physiology,Faculty of medicine,Benha university,Benha 13518,QG,Egypt.
Abstract
Background: Chronic kidney disease is a global public health problem that shortens lifespan by increasing the risk of cardiovascular disease. Aim: This study aimed to investigate the cardioprotective effect of erythropiotein (EPO) on uremic cardiomyopathy (UCM) and targeting the possible role of NFκβ. Methods: UCM was induced surgically in rats via a one-step 5/6th nephrectomy procedure. Serum level of Urea and Creatinine were measured to assess renal function. Also, EF%, FS% , LVDd & LVSd were estimated to assess the cardiac function . Moreover, tissue level of NFκβ, IL1 , IL6 and TNFα were measured to assess the possible mechanism .Results: UCM caused a significant increase in urea , creatinine , IL1 , IL6 , TNFα ,NFκβ , LVDd & LVSd with a significant decrease in EF% & FS%. Administration of EPO caused a significant improvement of the aforementioned UCM effects. Conclusion, EPO has cardioprotective effect in UCM targeting NFκβ.
Keywords
CKD; EPO; UCM; nuclear factor kappa beta (NF-κβ)
Statistics
Article View: 260
PDF Download: 358